According to the Zhitong Finance App, Zhaoyan Pharmaceutical (06127) released its report for the first quarter of 2024. Operating revenue was 325 million yuan (RMB, same below), down 12.07% year on year; net loss attributable to shareholders of listed companies was 272 million yuan, profit of 188 million yuan for the same period last year; basic loss per share was 0.36 yuan.
昭衍新药(06127)一季度归母净亏损2.72亿元
Zhaoyan Pharmaceutical (06127) lost 272 million yuan to mother in the first quarter
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.